Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESS-AKD: SGLT2 Inhibitors in Acute Kidney Disease
NCT06528405Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin, empagliflozin, canagliflozin in acute kidney failure (AKF), sponsored by National Taiwan University Hospital. Started Nov 2024; status: recruiting.
02
Drugs
dapagliflozinempagliflozincanagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NCT06528405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528405.